Cargando…

Managing thrombosis in cancer patients

Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer‐associated thrombosis are evolving. Here we review seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tzu‐Fei, Li, Ang, Garcia, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046582/
https://www.ncbi.nlm.nih.gov/pubmed/30046747
http://dx.doi.org/10.1002/rth2.12102
_version_ 1783339842729410560
author Wang, Tzu‐Fei
Li, Ang
Garcia, David
author_facet Wang, Tzu‐Fei
Li, Ang
Garcia, David
author_sort Wang, Tzu‐Fei
collection PubMed
description Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer‐associated thrombosis are evolving. Here we review several important topics related to cancer‐associated thromboembolism, including the pathogenesis, prevention, and management of this disease. Wherever possible, we include evidence from clinical trials, including the results of recently published trials that compared direct oral anticoagulants to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis.
format Online
Article
Text
id pubmed-6046582
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60465822018-07-25 Managing thrombosis in cancer patients Wang, Tzu‐Fei Li, Ang Garcia, David Res Pract Thromb Haemost Review Articles Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer‐associated thrombosis are evolving. Here we review several important topics related to cancer‐associated thromboembolism, including the pathogenesis, prevention, and management of this disease. Wherever possible, we include evidence from clinical trials, including the results of recently published trials that compared direct oral anticoagulants to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis. John Wiley and Sons Inc. 2018-05-01 /pmc/articles/PMC6046582/ /pubmed/30046747 http://dx.doi.org/10.1002/rth2.12102 Text en © 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Wang, Tzu‐Fei
Li, Ang
Garcia, David
Managing thrombosis in cancer patients
title Managing thrombosis in cancer patients
title_full Managing thrombosis in cancer patients
title_fullStr Managing thrombosis in cancer patients
title_full_unstemmed Managing thrombosis in cancer patients
title_short Managing thrombosis in cancer patients
title_sort managing thrombosis in cancer patients
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046582/
https://www.ncbi.nlm.nih.gov/pubmed/30046747
http://dx.doi.org/10.1002/rth2.12102
work_keys_str_mv AT wangtzufei managingthrombosisincancerpatients
AT liang managingthrombosisincancerpatients
AT garciadavid managingthrombosisincancerpatients